12 Best Future Stocks to Buy For the Long Term

5. Eli Lilly and Company (NYSE:LLY)

Average Upside Potential: 14.82%

Number of Hedge Fund Holders: 114

Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced positive topline results from the pioneering TOGETHER-PsA Phase 3b trial. This study is the first controlled pharmacologic trial to evaluate the combined use of an incretin therapy, Zepbound (tirzepatide), alongside a biologic, Taltz (ixekizumab).

The trial by Eli Lilly and Company (NYSE:LLY) focused on adults with active psoriatic arthritis/PsA who are also living with obesity or overweight with at least one weight-related condition. This is a demographic that represents ~65% of PsA patients in the US. The study met its primary endpoint at 36 weeks, with 31.7% of patients receiving the combined treatment achieving both a 50% improvement in PsA activity and at least a 10% reduction in body weight. In stark contrast, only 0.8% of patients receiving Taltz monotherapy reached this dual goal.

Furthermore, the combination therapy delivered a 64% relative increase in the proportion of patients achieving ACR50 compared to Taltz alone. These results suggest that treating underlying obesity directly reduces the overall burden of PsA. Safety findings were consistent with the known profiles of both medications; the most common adverse events for the combination arm included nausea, diarrhea, constipation, and injection site reactions, while the Taltz-only arm primarily saw injection site reactions and upper respiratory tract infections.

Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals in the US, Europe, China, Japan, and internationally.